Cardiac Energetic Efficiency as a Predictor of Future Outcomes

Abstract

Cardiac energetic efficiency (CEE) the ratio of the heart's mechanical work output to its total energy consumption has emerged as a critical biomarker in cardiovascular medicine. This review synthesizes recent evidence underscoring the clinical and prognostic significance of CEE, detailing its pathophysiological underpinnings, epidemiological impact, diagnostic modalities, and implications for patient management. We discuss risk factors influencing CEE, its relationship with cardiovascular outcomes, and the integration of CEE assessment into routine practice, supported by current guidelines and emerging therapeutic interventions.

Introduction

The concept of cardiac energetic efficiency (CEE) has garnered increasing attention in recent years, supported by robust clinical and experimental evidence. Traditionally, cardiac function assessment has relied on structural and hemodynamic parameters; however, CEE provides a mechanistic window into the interplay between myocardial energy metabolism and contractile function. The ability to predict adverse cardiovascular outcomes through CEE measurement holds promise for risk stratification, early intervention, and personalized medicine approaches in both acute and chronic cardiac conditions.

Epidemiology / Disease Burden

Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide, accounting for an estimated 18 million deaths annually. Heart failure (HF) alone affects over 64 million individuals globally. Emerging epidemiological data suggest that impaired CEE is not only prevalent among patients with overt heart failure but also detectable in subclinical stages of various cardiomyopathies, hypertensive heart disease, and ischemic heart disease. Population-based studies indicate that reduced CEE independently correlates with adverse cardiovascular events, hospitalizations, and all-cause mortality, highlighting its relevance across diverse clinical settings.

Pathophysiology

CEE is determined by the balance between myocardial oxygen consumption (MVO₂) and external cardiac work. Under physiologic conditions, the heart efficiently couples ATP hydrolysis to contractile function. In pathological states such as ischemia, hypertrophy, or metabolic derangements, this coupling becomes disrupted, leading to energy wastage and reduced mechanical output. Mitochondrial dysfunction, altered substrate utilization (e.g., increased reliance on glucose or fatty acids), and impaired calcium cycling are central to the decline in CEE. These alterations not only precede clinical deterioration but also contribute to disease progression through maladaptive remodeling, apoptosis, and impaired myocardial reserve.

Risk Factors

Several modifiable and non-modifiable risk factors adversely affect CEE. Age-related mitochondrial decline, chronic ischemia, diabetes mellitus, obesity, hypertension, and genetic mutations in sarcomeric or mitochondrial proteins are well-established contributors. Lifestyle factors, including physical inactivity and poor dietary habits, exacerbate metabolic inefficiency. Additionally, exposure to cardiotoxic agents such as certain chemotherapeutics can precipitate energetic impairment even in the absence of overt structural heart disease.

Clinical Features

While decreased CEE per se is not directly symptomatic, it manifests clinically through the phenotypes of heart failure, exercise intolerance, and arrhythmogenic risk. Patients with impaired CEE often exhibit reduced exercise capacity, early fatigue, and symptoms disproportionate to structural findings. In advanced disease, low CEE correlates with worsening New York Heart Association (NYHA) class, elevated natriuretic peptides, and a heightened risk of sudden cardiac death.

Diagnosis

Accurate quantification of CEE necessitates integration of imaging and metabolic assessments. Non-invasive techniques such as echocardiography with pressure-volume loop analysis, cardiac magnetic resonance imaging (MRI) with phosphorus-31 magnetic resonance spectroscopy (MRS), and positron emission tomography (PET) using radiolabeled substrates allow estimation of myocardial efficiency in vivo. Biomarkers reflecting mitochondrial function and substrate utilization, including lactate, free fatty acids, and ketone bodies, provide additional diagnostic insights. Standardized protocols and reference ranges remain an area of ongoing research, with recent consensus statements advocating for the inclusion of CEE assessment in advanced heart failure evaluation.

Treatment & Management

Therapeutic strategies aimed at improving CEE focus on optimizing myocardial energy supply and demand. Pharmacologic interventions include beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor-neprilysin inhibitors (ARNIs), and sodium-glucose cotransporter 2 (SGLT2) inhibitors, all of which have demonstrated favorable effects on cardiac energetics and outcomes in randomized controlled trials. Lifestyle interventions such as structured exercise programs and dietary modification improve mitochondrial function and metabolic flexibility. In select cases, device-based therapies like cardiac resynchronization therapy (CRT) enhance mechanical efficiency by restoring synchrony and reducing wasted myocardial work.

Recent Advances / Emerging Therapies

Recent advances have illuminated the therapeutic potential of metabolic modulators agents that shift substrate utilization toward more energetically favorable pathways. Perhexiline, trimetazidine, and ranolazine have shown promise in improving CEE, particularly in ischemic and hypertrophic cardiomyopathy. Novel gene therapies targeting mitochondrial biogenesis and calcium handling are under investigation. Additionally, machine learning algorithms leveraging large-scale imaging and metabolomic data are enabling personalized prediction of CEE and tailoring of therapeutic interventions. The integration of wearable technologies and remote monitoring is also facilitating real-time assessment of cardiac energetics in ambulatory settings.

Guideline Recommendations

Major cardiology societies, including the American Heart Association (AHA) and European Society of Cardiology (ESC), recognize the importance of metabolic assessment in advanced heart failure management. Recent guidelines endorse the use of imaging-based efficiency metrics in research and select clinical contexts, particularly for prognostication and therapy monitoring. There is a growing consensus on the need for standardized CEE measurement protocols and incorporation into risk stratification algorithms. Multidisciplinary collaboration involving cardiologists, radiologists, and metabolic specialists is recommended to optimize patient outcomes.

Conclusion

Cardiac energetic efficiency represents a transformative biomarker in cardiovascular medicine, bridging the gap between molecular pathophysiology and clinical outcomes. Its assessment provides actionable insights for early detection, risk stratification, and individualized management of patients with cardiovascular disease. Ongoing research and technological innovation will continue to refine diagnostic accuracy, expand therapeutic options, and integrate CEE into routine clinical practice, ultimately improving prognosis and quality of life for affected individuals.